Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 12/20 | 0.72 |
| ▸ | GPR174 | Q9BXC1 | 9/20 | 0.72 |
| ▸ | GPR34 | Q9UPC5 | 6/20 | 0.72 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.70 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.70 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.70 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.70 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.70 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.70 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.70 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.64 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31442365 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL31442370 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL274812 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL14953735 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL31442542 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL21464913 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL14924219 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL14882712 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL13854646 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL31442348 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247981-B2 | Method of diagnosing cancer based on lipidomic analysis of a body fluid | FONS JK GROUP, A.S. (CZ) | 2025-03-11 | — | — | US | claimed |
| EP-3575793-B1 | A METHOD OF DIAGNOSING CANCER BASED ON LIPIDOMIC ANALYSIS OF A BODY FLUID | FONS JK GROUP A S (CZ) | 2023-07-19 | — | — | EP | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | disclosed |
| EP-4470545-B1 | CELL-FREE LIPOASPIRATE-DERIVED PREPARATION, COMPOSITIONS COMPRISING THE PREPARATION AND USES THEREOF | Linio Biotech Ltd (FI) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025095862-A1 | A COMPOSITION, A METHOD OF MAKING THE COMPOSITION AND ITS USES THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025080208-A1 | NUCLEIC ACID INHIBITORS OF CERAMIDE SYNTHESIS AND USES THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-04-17 | — | — | WO | disclosed |
| US-20250093343-A1 | IMPROVED EXOSOME PROFILING FOR THERAPY AND DIAGNOSIS | NEURODEX, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12247981-B2 | Method of diagnosing cancer based on lipidomic analysis of a body fluid | FONS JK GROUP, A.S. (CZ) | 2025-03-11 | — | — | US | disclosed |
| US-20240423923-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON ADMINISTRATION, AND USES | AGS THERAPEUTICS SAS (FR) | 2024-12-26 | — | — | US | disclosed |
| WO-2024248380-A1 | PHOSPHOLIPID-BASED SURFACTANT USING SKIN FLORA AND MANUFACTURING METHOD THEREOF | 코스맥스에이비 주식회사 | 2024-12-05 | — | — | WO | disclosed |
| US-20240398871-A1 | CELL-FREE LIPOASPIRATE-DERIVED PREPARATION, COMPOSITIONS INCLUDING THE PREPARATION AND USES THEREOF | Linio Biotech Ltd (FI) | 2024-12-05 | — | — | US | disclosed |
| EP-3575793-B1 | A METHOD OF DIAGNOSING CANCER BASED ON LIPIDOMIC ANALYSIS OF A BODY FLUID | FONS JK GROUP A S (CZ) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023112004-A1 | IMPROVED EXOSOME PROFILING FOR THERAPY AND DIAGNOSIS | NEURODEX, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20220378850-A1 | MICROBIAL CONSORTIA | SIOLTA THERAPEUTICS INC (US) | 2022-12-01 | — | — | US | disclosed |
| US-11369644-B2 | Microbial consortia | SIOLTA THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| CN-113038957-A | Microbial population | 谢尔塔治疗公司 | 2021-06-25 | — | — | CN | disclosed |
| US-20210077541-A1 | MICROBIAL CONSORTIA | SIOLTA THERAPEUTICS, INC. | 2021-03-18 | — | — | US | disclosed |
| EP-3773645-A1 | MICROBIAL CONSORTIA | Siolta Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019199895-A1 | MICROBIAL CONSORTIA | SIOLTA THERAPEUTICS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | NLN, DCX, CNTN1 | P2RY10 2851/4885GPR174 1995/4885GPR34 3417/4885 |
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | P2RY10 512/4885GPR174 92/4885GPR34 240/4885 |
| US-20240423923-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON ADMINISTRATION, AND USES | CHMP4B, ALG1, FUCA2 | P2RY10 1328/4885GPR174 3428/4885GPR34 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.